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Abstract
Rationale: Cartilaginous metaplasia of vascular smooth muscle (VSM) is characteristic for arterial calcification in
diabetes and uremia and in the background of genetic alterations in matrix Gla protein (MGP). A better understanding
of the molecular details of this process is critical for the development of novel therapeutic approaches to VSM
transformation and arterial calcification.
Objective: This study aimed to identify the effects of bioflavonoid quercetin on chondrogenic transformation and
calcification of VSM in the MGP-null mouse model and upon TGF-β3 stimulation in vitro, and to characterize the
associated alterations in cell signaling.
Methods and Results: Molecular analysis revealed activation of β-catenin signaling in cartilaginous metaplasia in
Mgp-/- aortae in vivo and during chondrogenic transformation of VSMCs in vitro. Quercetin intercepted chondrogenic
transformation of VSM and blocked activation of β-catenin both in vivo and in vitro. Although dietary quercetin
drastically attenuated calcifying cartilaginous metaplasia in Mgp-/- animals, approximately one-half of total vascular
calcium mineral remained as depositions along elastic lamellae.
Conclusion: Quercetin is potent in preventing VSM chondrogenic transformation caused by diverse stimuli.
Combined with the demonstrated efficiency of dietary quercetin in preventing ectopic chondrogenesis in the MGP-null
vasculature, these findings indicate a potentially broad therapeutic applicability of this safe for human consumption
bioflavonoid in the therapy of cardiovascular conditions linked to cartilaginous metaplasia of VSM. Elastocalcinosis is
a major component of MGP-null vascular disease and is controlled by a mechanism different from chondrogenic
transformation of VSM and not sensitive to quercetin.
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Introduction
In the normal vasculature, the principal function of smooth
muscle cells is contraction to regulate blood pressure and
blood flow throughout the body [1]. In contrast to the other
terminally-differentiated muscle cells, cardiac and skeletal,
vascular smooth muscle cells (VSMCs) undergo a unique
phenotypic modulation during normal development, and in the
physiologic response to blood vessel remodeling or injury. This
is associated with decreased expression of VSMC-specific
contractile genes and increased cell proliferation and migration.
However, there is growing evidence that this phenotypic
plasticity of VSMCs contributes to vascular disease by allowing
for differentiation to inappropriate lineages [1–3]. For example,
in diabetic arteriosclerosis VSMCs undergo osteogenic
transformation, losing contractile gene expression and
depositing a calcified bone-like matrix. Together this results in
increased vessel stiffness and decreased compliance, a strong
predictor of cardiovascular risk [4].
Recent mechanistic studies reveal the complexity of
phenotypic instability in VSMCs. The literature in this field is
extensive and identifies diverse regulators including, but not
limited to, growth factors, inflammatory cytokines, calcium-
phosphate homeostasis, oxidized phospholipids, retinoic acid
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and mechanical stress, and involves multiple signaling
pathways including MAPK kinases, Rho, Notch, BMP and β-
catenin signaling (reviewed in [5–7]).
Lineage tracing studies have demonstrated that VSMC-
derived hyperproliferative cells play a role in neointimal
formation induced by either injury [8] or atherosclerosis [9], and
that osteochondrogenic transformation of VSMCs associates
with calcification of the arterial media [10–13] as well as
atherosclerotic calcification [14]. Vascular calcification (or
pathologic calcium phosphate deposition in the blood vessels)
is a common complication associated with diabetes,
hypercholesterolemia, chronic renal insufficiency and
osteoporosis, and is highly correlated with cardiovascular
disease mortality. Its clinical consequences include stroke,
amputation, ischemic heart disease, and complications during
artery stenting. In addition, vascular calcification is now
recognized as a marker of atherosclerotic plaque burden
[15,16]. The incidence of vascular calcification also correlates
with age, putting a growing percentage of our population at risk
as life expectancy increases.
A decrease in circulating and local inhibitors of
mineralization, especially in dialysis patients with chronic
kidney disease, appears to significantly contribute to
calcification. One of the major anti-calcific factors is matrix Gla
protein (MGP), a 10 kDa polypeptide containing calcium-
binding γ-carboxyglutamic acid (Gla) residues and
phosphoserine residues. In the vasculature, MGP is expressed
in vascular smooth muscle (VSM) and endothelium [17,18].
MGP polymorphisms have been linked to coronary artery
calcification in patients [19,20], while in mice genetic loss of
MGP leads to cartilaginous metaplasia and extensive
calcification of the tunica media [21]. MGP-null arterial disease
has been described primarily as a product of chondrogenic
transformation of Mgp-/- VSM resulting in the ectopic formation
of cartilage in the vessel wall, extensive calcification, and
ultimately rupture of the blood vessels soon after birth [21].
While mechanisms underlying the osteogenic transformation of
VSM induced by warfarin [10–13] and by hyperphosphatemia
[22,23] are emerging [7,24,25], the chondrogenic
transformation of vascular cells that is prominent in uremia-
and diabetes-associated medial calcification [26,27] is not well
understood. The Mgp-/- vasculature is an excellent model for
mechanistic analysis of chondrogenic transformation in VSM
because 97% of the chondrocyte-like cells in arterial
cartilaginous metaplasia originate from VSM [13] suggesting a
minimal (if any) contribution by circulating or resident
multipotent mesenchymal progenitors.
With a growing mechanistic understanding, treatment options
for vascular diseases are rapidly developing. In particular,
emerging interest has been focused on the protective effects of
flavonoid-rich diets in cardiovascular disease. The reported
beneficial effects of the major bioflavonoid, dietary quercetin, in
humans include lower blood pressure and LDL levels and
overall reduced cardiovascular disease-related mortality
[26–29]. In animal models, quercetin effectively alleviated
atherosclerosis [30,31] and attenuated warfarin-induced
hypertension and elastocalcinosis [12]. Quercetin has anti-
inflammatory, anti-oxidative and anti-proliferation effects. In
addition, we have found that in VSMCs quercetin inhibits β-
catenin signaling, central for osteogenic transformation of these
cells, and vascular calcification induced by warfarin [12,25]. β-
catenin is a multi-tasking molecule regulating developmental
and homeostatic processes. It is an integral part of adherent
junctions and the key mediator of the canonical Wnt/β-catenin
signaling cascade, and has been shown to cross-talk directly
with non-Wnt pathways [32]. During development Wnt/β-
catenin signaling plays a manifold role and promotes
physiological chondrocyte maturation [33] as well as vascular
remodeling and differentiation [34]. In adult vessels, the β-
catenin pathway is usually dormant but activates in disease
[35]. In particular, a critical role for β-catenin signaling has been
shown in warfarin-induced calcification [36,37]. Further, Wnt/β-
catenin signaling has also been implicated in BMP2-induced
aortic mineralization in the diabetic LDLR-/- mice [38] and in
calcification of heart valves [39]. Here, we investigated β-
catenin signaling associated with chondrogenic transformation
of Mgp-/- VSM, and examined the efficiency of quercetin in
alleviating the MGP-null vascular disease.
Materials and Methods
Animals
4.5 to 5 week-old C57BL/6J wild-type mice (Mgp+/+) and
mice deficient in MGP (Mgp-/-
) were used in this study. MGP-deficient mice were a kind gift
from Dr. Karsenty, Columbia University, New York. Mice were
genotyped using standard PCR for Mgp. All procedures were
approved by the institutional animal care and use committees
at the University of Maryland Medical School (protocol #:
0912010) and the University of North Carolina School of
Medicine, and were conducted in compliance with National
Institutes of Health guidelines for the care and use of laboratory
animals.
Quercetin treatment
Quercetin (Quercegen, Newton, MA) was administered as a
dietary supplement (0.02% w/w in drinking water) to weaned
pups for 2 weeks. Alternatively, quercetin was given to lactating
Mgp+/- females immediately after they gave birth to the
progeny and continued throughout the 3-week breastfeeding
period. Weaned Mgp-/- pups continued to receive quercetin in
drinking water for an additional 2 weeks.
Immunohistochemistry and Histological Staining
Frozen 10 µm sections of freshly-dissected aortas fixed in
4% paraformaldehyde were stained for proteoglycan deposition
and calcified matrix using the alcian blue and von Kossa silver
nitrate methods, respectively, according to standard protocols
[40].
Immunofluorescence was performed using the standard
protocol. Briefly, tissue was blocked with 10% goat serum for
30 minutes at room temperature. Tissue sections were
incubated with primary antibodies diluted in 1% goat serum
overnight at 4°C and secondary antibodies diluted in PBS for
1.5 hours at room temperature. Nuclei were counterstained
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with 4',6-diamidino-2-phenylindole (DAPI). Primary antibodies
used were rabbit anti-β-catenin (1:80; Santa Cruz
Biotechnology) and rabbit anti-Ki67 (1:100; Abcam), detected
with a secondary Dylight 549-conjugated goat anti-rabbit
antibody (1:400; Jackson ImmunoResearch); mouse anti-type
II collagen antibody (a kind gift of Dr. Thomas Linsenmayer),
detected with a secondary Alexa 488-conjugated goat anti-
mouse antibody; and mouse anti-smooth muscle actin antibody
directly conjugated to fluorescein isothiocyanate (FITC).
Images were collected using a Leica DMIL inverted microscope
equipped with a SPOT RT3 real-time CCD camera (Diagnostic
Instruments).
Morphologic Analysis
For morphologic analyses, serial sections spaced 100 µm
apart along a 1 mm length of descending aorta from
heterozygous (Mgp+/-
), Mgp-/-, and quercetin-treated Mgp-/- (Mgp-/- +Querc)
animals were analyzed for chondrogenic lesions and average
thickness of tunica media. For each animal, the average value
of 4-5 serial sections was used. Mean and standard error
values used for graphical display were calculated from the
average values of each animal. All values were normalized to
wild-type animals (set at 100%).
Cell culture and Luciferase Analysis
Murine aortic smooth muscle cells were obtained by a
modification of the explant method described by Ross [41].
Briefly, medial tissue was isolated from segments of thoracic
aorta from wild-type C57BL/6J (Mgp+/+) mice. Small pieces of
tissue (1 to 2 mm) were loosened by a 1-hour incubation at
37°C in medium supplemented with 165 U/mL collagenase
type I. Partially digested tissues were placed in 6-well plates
and cultured for 10 days in DMEM supplemented with 20%
FBS at 37°C in a humidified atmosphere containing 5% CO2.
Cells that migrated from the explants were collected and
maintained in growth medium (DMEM containing 10% FBS and
100 U/mL of penicillin and 100 µg/mL of streptomycin). To
confirm that the cells isolated were VSMCs, α-smooth muscle
actin expression was confirmed by immunofluorescence (data
not shown). For experiments, cells were used at passages 2
and 3.
The A10 clonal embryonic rat aortic smooth muscle cell line
(ATCC, Manassas VA) was also maintained in growth medium.
A stable β-catenin-dependent luciferase reporter cell line was
established by transducing A10 VSMCs with the Cignal
Lentiviral TCF/LEF luciferase reporter (SA Biosciences),
according to manufacturer’s protocol, followed by a 2-week
selection with puromycin (10 µg/mL). Luciferase activity in
whole cell lysates was measured in a 96-well plate
luminometer (Harta Instruments, Bethesda MD) using the
Promega Luciferase Assay Kit and was normalized to the total
lactate dehydrogenase (LDH) present in whole cell lysates,
measured using a commercial LDH activity kit (BioVision, San
Francisco CA). LDH activity in the culture medium was also
measured to determine cell viability.
To induce chondrogenic transformation, VSMCs were
seeded at high density (2.5x105 cells in 10 µL volume) and
cultured in chondrogenic medium (ChoM) [DMEM–high
glucose supplemented with 10−7 mmol/L dexamethasone, 0.1
mmol/L ascorbic acid (Wako Chemicals, VA), 1% ITS premix
(BD Biosciences, NJ), 1 mmol/L sodium pyruvate, 0.35 mmol/L
L-proline, 4 mmol/L L-Glutamine (Invitrogen), 1% Pencillin–
Streptomycin (Invitrogen), and 10 ng/mL TGF-β3 (ProSpec,
NJ)] in the presence or absence of quercetin (50 µmol/L) or
recombinant Dkk1 (0.5 µg/mL; R&D Systems) at 37°C, 5%
CO2. Medium was changed twice a week for up to 14 days.
Sulfated glycosaminoglycan (GAG) synthesized by cultured
VSMCs was detected by fixing them in 4% PFA and staining
with 1% Alcian blue (8GX) dissolved in 0.1 N HCl. For
quantitative analysis, Alcian blue was extracted with 4 M
guanidine hydrochloride and absorbance at 590 nm was
measured using an Optima spectrophotometer (PolarStar). Cell
density was estimated using WST substrate (Dojindo).
qRT-PCR
mRNA was isolated using the RNeasy micro kit (Qiagen) and
reverse transcription was performed with MaximaRT kit
(Thermo, Fisher). Quantitative real-time PCR was performed
according to the standard protocol with EVA green chemistry in
a CFX96 thermocycler (Bio-Rad) using the primers in Table 1.
Relative change in gene expression was calculated by the
ΔΔCt method using Microsoft Excel.
Calcium Determination
Aortas were dried at 55°C overnight and then dissolved in
0.1N hydrochloric acid (HCl) overnight. Calcium content was
determined biochemically using the Calcium (CPC) LiquiColor
kit as measured with o-Cresolphthalein (Stanbio). Calcium
content of the aorta was normalized to dry weight of the tissue
prior to HCl extraction.
Tissue Preparation for Gene Expression Analysis using
RT2 Profiler PCR Arrays
Aortic tissue from 5 week old mice was disrupted by rapid
agitation in the presence of a stainless steel bead (5 mm mean
diameter) and lysis buffer using a TissueLyser (2 min at 20Hz,
twice; Qiagen). Total RNA was isolated following the RNeasy
Fibrous Tissue micro kit protocol (Qiagen) according to the to
the manufacturer’s instructions and quantified with NanoDrop
spectrophotometer (Thermo Scientific) prior to storage at
−80°C. Reverse transcription was performed using 1 µg of
RNA according to SA Biosciences’ recommendations using the
RT2 First Strand kit. Gene expression analysis was done using
the WNT Signaling Pathway PCR Array (PAMM-043), WNT
Signaling Targets PCR Array (PAMM-243) and Osteogenesis
PCR Array (PAMM-026). ΔΔCt based fold-change calculations
were performed using the RT² Profiler PCR Array Data
Analysis Template v3.2. In this software standard deviation is
calculated for Ct values and not for final fold-changes in
expression.
Statistical Analysis
The data are presented as mean ± standard error. For
experiments containing only 2 groups, significance was
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determined by comparison using Wilcoxon-Mann-Whitney test.
For experiments containing more than 2 groups, Levene’s test
was used to determine equality of variance (homoscedasticity)
followed by 1-way analysis of variance (ANOVA) and Tukey-
Kramer post-hoc analysis for comparison between groups. A p-
value of < 0.05 was considered to be statistically significant. *,
p <0.05; **, p < 0.01; ***, p<0.001.
Results
Analysis of proliferation in chondroplastic areas of
Mgp-/- aortae
Mgp-/- mice are characterized by the presence of ectopic
cartilage in the tunica media [21]. To identify potential
mechanisms of the formation of cartilaginous lesions, we first
analyzed the possible contribution of increased cell
proliferation. Foci of chondrogenic metaplasia were readily
detected as areas with the characteristic appearance of
rounded chondrocyte-like cells embedded in glycoprotein-rich
matrix positive for Alcian Blue staining and cartilaginous
collagen type II (Figure 1A), in agreement with previous studies
[13,21,42]. We then performed immunohistochemistry for Ki67,
a marker of cell proliferation, (Figure 1B) and determined the
proportion of the proliferating cells positive for Ki67, compared
to total nuclei visible by DAPI nuclear counterstain, in wild-type
and Mgp-/- aortae. Aortic tissue isolated from newborn, 7- and
30-day old animals was examined. 3 random cross-sections of
aortae from each animal were analyzed. The percentage of
Ki67-positive proliferating cells was similar between wild-type
and Mgp-/- aortae at all ages examined (Figure 1C),
suggesting that the formation of cartilaginous metaplasia is
driven by phenotypic transformation, rather than proliferation,
of VSMCs.
Activation of β-catenin signaling in Mgp-/- aortae
Canonical β-catenin signaling regulates normal physiologic
chondrogenesis [33]. Here, we investigated the association
between activation of this signaling cascade and chondrogenic
transformation in Mgp-/- aortae using a qRT-PCR-based
microarray of 84 components and regulators of Wnt/β-catenin
signaling (4.5 week old Mgp-/- and wild-type mice, N=6). A
number of activating Wnt ligands and transcriptional co-
activators of β-catenin signaling such as Ccnd3, Pitx2 and Lef1
are induced in the Mgp-/- aortae (Table 2), although arterial
expression levels of the canonical Wnts detected by the qRT-
PCR were very low in both wild-type and Mgp-/- tissue (with
only Wnt3a threshold cycle number being less than 35). In
addition, the drastic down-regulation of sclerostin, an inhibitor
of Wnt signaling, further indicates activation of this pathway in
Mgp-/- arteries (Table 2).
To address this possibility, we used the qRT-PCR-based
array approach to study expression of 84 β-catenin target
genes in Mgp-/- and wild-type aortae (N=6). This analysis
revealed a higher than 2-fold induction in 50% of the β-catenin
target genes in the Mgp-/- aortae with 28 genes showing a
statistically significant change (Table 3; p<0.05) and 16
additional genes showing a trend towards induction (p>0.05).
Importantly, many of the β-catenin target genes significantly
upregulated in the Mgp-/- arterial tissue are related to
osteochondrogenic transformation or VSMC de-differentiation
(Table 3). These results indicate β-catenin signaling is
activated in the absence of MGP and that its activation may
contribute to chondrogenic transformation in VSM.
Chondrogenic transformation of VSMCs in vitro:
activation of β-catenin signaling
To determine whether activation of β-catenin signaling
directly associates with chondrogenic transformation of VSM, in
contrast to being potentially induced by systemic factors in the
Mgp-/- mice, we employed an in vitro system in which the A10
Table 1. Primer sequences for mouse genes analyzed by real-time PCR.
Gene Accession # Forward primer Reverse primer
β-catenin targets    
Lrp6 NM_008514 ggtgtcaaagaagcctctgc gctcgaggactgtcaaggtc
Tcf4 NM_013685 cgaaaagttcctccgggtttg cgtagccgggctgattcat
Numb NM_010949 cttcccagttaagtacctcggc cccgtttttccaaagaagcct
CyclinD1 (cycD1) NM_007631 gcgtaccctgacaccaatctc ctcctcttcgcacttctgctc
Chondrogenic markers   
Sox9 NM_011448 gttgtaacaccagcagcgtcaag tgacatactccactttggccacct
Type II collagen (Col II) NM_031163 caccgaaagtttaagcacaccca aaataaccctgcccacactcttg
Aggrecan (Agg) NM_007424 atgccacaagtcacagaaaccacg aaggcagtcacagcattgttgagc
Indian hedgehog (Ihh) NM_010544 cgtgaccgaaataagtatggact gctgctggttctgtatgattg
MMP13 NM_008607 tggagtgcctgatgtgggtgaata tggtgtcacatcagaccagacctt
TG2 NM_009373 aggtgtccctgaagaacccacttt ttccacagacttctgctccttggt
Housekeeping genes   
Ribosomal protein L19 (Rpl19) NM_009078 aagaggaagggtactgccaatgct tgaccttcaggtacaggctgtgat
beta-actin NM_007393 taatttctgaatggcccaggtct ctggctgcctcaacacctcaa
doi: 10.1371/journal.pone.0076210.t001
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Figure 1.  Cartilaginous metaplasia and cell proliferation in
the Mgp-/- aorta.  A, Detection of cartilage matrix using Alcian
blue staining for GAG deposition and immunostaining for
Collagen type II (Collagen II) protein on adjacent sections of
aorta from 4.5 week old wild-type (Mgp+/+) and Mgp-/-
animals. Scale = 50 µm. Dashed lines denote internal and
external elastic lamina. B, Representative immunostaining for
cell proliferation marker, Ki67 (white, red) [nuclei
counterstained with DAPI (blue)] in 30 day old Mgp+/+ and
Mgp-/- aortae. Scale = 50 µm. C, Quantitation of the
percentage of Ki67-positive nuclei compared to total nuclei in
Mgp+/+ and Mgp-/- aortic tissue from animals at birth (d0,
N=3), at 7 days old (d7, N=4), and at 30 days old (d30, N=4).
Four sections per animal were analyzed.
doi: 10.1371/journal.pone.0076210.g001
rat aortic VSMC line or primary mouse VSMCs (P2-3) were
induced to undergo chondrogenic transformation in high-
Table 2. Changes in expression of genes in the Wnt
signaling pathway in Mgp-/- compared to wild-type aortae.
Gene Gene product Fold change p-value
Role in Wnt/β-
catenin signaling
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Negative regulator
of Wnt signaling [61]
Wif1 Wnt inhibitory factor 1 -8.56* 0.013  
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density micromass cultures stimulated by dexamethasone and
TGF-β3 [43]. Within two weeks in culture, both rat and mouse
VSMCs underwent chondrogenic transformation, evidenced by
the formation of characteristic glycosaminoglycan (GAG)-rich
cartilaginous nodules (Figure 2A). This was accompanied by
activation of β-catenin signaling, detected by increased
expression of a β-catenin-dependent luciferase transgene in
A10 cells (Figure 2B, 8.16 ±2.02-fold, p<0.05).
Chondrogenic transformation of VSMCs in vitro:
attenuation by quercetin
Quercetin has been characterized as a potent inhibitor of β-
catenin signaling, and in VSMCs quercetin stabilizes the
contractile phenotype [25]. Here we show that quercetin
significantly attenuated the activation of β-catenin signaling in
chondrogenic micromass cultures of A10 cells (Figure 2B) and
also significantly reduced chondrogenic differentiation in these
cells as evidenced by a reduction in GAG-positive matrix
detected with Alcian Blue stain (Figure 2C). To determine
whether the observed inhibition of β-catenin signaling caused
the reduction in GAG synthesis, we treated chondrogenic
micromass cultures with recombinant Dkk1, a known inhibitor
of the canonical β-catenin pathway [44]. Dkk1 prevented both
increased expression of the β-catenin-dependent luciferase
reporter (Figure 2D) and deposition of cartilaginous GAG
matrix by A10 VSMCs (Figure 2E), demonstrating a critical role
for activation of β-catenin signaling in the chondrogenic
transformation of VSMCs in vitro.
Similar to its effects on the A10 VSMC line, quercetin
significantly reduced GAG deposition by primary mouse aortic
VSMCs treated with chondrogenic medium in micromass
culture without affecting cell survival as evidenced by
unchanged levels of LDH activity in the culture medium (Figure
3A). Analysis of stage-specific markers of chondrogenesis
using qRT-PCR showed that quercetin prevented induction of
both early (Sox9, collagen type II, and aggrecan) and late (Ihh,
MMP13, and TG2) markers (Figure 3B), identifying this
flavonoid as a potent inhibitor of chondrogenic transformation
in VSMCs and suggesting the potential therapeutic value of
quercetin in preventing chondrogenic transformation of VSM in
vivo. In addition, qRT-PCR analysis revealed that the
expression of four endogenous β-catenin target genes induced
during chondrogenic transformation of VSMCs was prevented
by quercetin indicating inhibition of β-catenin signaling (Figure
Table 2 (continued).












Aortic tissue from 4.5 week old animals was analyzed using a qRT-PCR-based
microarray N=6. * p<0.05; ** p<0.01; *** p<0.001.
doi: 10.1371/journal.pone.0076210.t002
Table 3. Changes in expression of Wnt/β-catenin target
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3C). Further, treatment of the primary VSMC micromasses with
the β-catenin pathway inhibitor Dkk1 blocked GAG-rich matrix
deposition (Figure 3D), mimicking the effect of quercetin and
implicating the β-catenin signaling pathway as a major target of
quercetin-mediated inhibition of chondrogenic transformation in
cultured VSMCs.
Quercetin reduces calcium accrual in Mgp-/- aortae
Taking into consideration that extensive calcification of
chondrogenic metaplasia is characteristic for MGP-null
vascular disease, we examined whether quercetin treatment
alleviates calcification in MGP-deficient animals. After weaning,
we treated Mgp-/- and Mgp+/- pups for 2 weeks with dietary
quercetin (0.02% w/w in drinking water [30]) and analyzed total
calcium content in the aortae biochemically by the o-
cresolphthalein complexone method. We found that quercetin
treatment associated with a significant 20.0±2.1% (p<0.001)
reduction in total calcium content of Mgp-/- aortic tissue (Figure
4A), although aortic calcium levels in the quercetin-treated
Mgp-/- animals remained significantly higher than those in
heterozygous littermates. In addition, quercetin treatment
associated with a significant reduction in the expression of
osteogenic genes in Mgp-/- aortic tissue (Table 4).
We hypothesized that quercetin may prevent the de novo
formation of calcifying cartilaginous metaplasia but not reverse
calcification already present in 3 week old animals at weaning.
Therefore, to affect younger animals we treated newborn
Mgp-/- mice with quercetin for 5 weeks (via the lactating moms
until weaning and then in the drinking water as described
above) and analyzed calcium accrual in these mice compared
to Mgp+/- littermates. Quercetin treatment from birth produced
a 36.3±1.7% (p<0.01) reduction in total calcium content of
Mgp-/- aortic tissue (Figure 4B), almost twice what was
observed in animals treated with quercetin for only 2 weeks.
However, calcium levels in the quercetin-treated Mgp-/- aortae
still remained significantly elevated. To examine this
phenomenon further, localization of calcium phosphate
deposits in the arterial walls was detected with von Kossa
staining (Figure 4C). Excessive calcium phosphate deposits
aligning with elastic lamellae were present in both untreated
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Fzd7 Frizzled 7 -4.05* 0.043
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capacity of hMSCs [81]
Aortic tissue from 4.5 week old animals was analyzed using a qRT-PCR-based
microarray. N=6. * p<0.05; ** p<0.01; *** p<0.001.
doi: 10.1371/journal.pone.0076210.t003
elastocalcinosis accounts for the remaining 64% of calcium
deposits in quercetin-treated mice thus identifying
elastocalcinosis as a major contributor to MGP null vascular
disease. In contrast, the massive calcified zones corresponding
to cartilaginous metaplasia were absent in quercetin-treated
Mgp-/- mice, indicating that in vivo chondrogenic transformation
of VSM is sensitive to quercetin treatment.
Dietary quercetin alleviates cartilaginous metaplasia
We next analyzed the reduction of cartilaginous metaplasia
by quercetin in more detail. Aortae were collected from Mgp-/-
mice treated with quercetin for 4.5 weeks and vessel wall
morphology was analyzed along a 1mm long aortic segment
using serial tissue sections collected 100 µm apart (Figure 5A).
Quercetin diet prevented cartilaginous metaplasia (indicated by
dashed lines) and improved gross morphology of the Mgp-/-
aortic wall (Figure 5B). Quantitatively, quercetin treatment
significantly reduced the proportion of cartilaginous lesions in
the circumference of vessel wall from 59.6±7.3% in the
untreated Mgp-/- mice (N=5) to 13.3±3.1% in the quercetin
treated animals (N=6, p<0.01) (Figure 5C). Accordingly, we
detected an approximately 30% reduction in arterial wall
thickness (64.2±5.0 µm in quercetin-treated Mgp-/- mice
compared to 90.1±9.9 µm in untreated Mgp-/- animals),
rendering this parameter similar to that of the control aortae
(Mgp+/-, N=3) (Figure 5D).
Further, qRT-PCR analysis revealed that expression of
cartilaginous extracellular matrix proteins and transcription
factors associated with chondrogenesis [45,46] were increased
in Mgp-/- animals, and this increase was significantly
attenuated in quercetin-treated Mgp-/- animals (Table 5). Of
note, both early and late markers of chondrogenesis were
attenuated by quercetin, implying that the prevention of
chondrogenic transformation of VSM by this flavonoid in vivo is
similar to its action in vitro.
Dietary quercetin blocks nuclear accumulation of β-
catenin protein in Mgp-/- aortae
Elaborating on our findings that the inhibition of
chondrogenesis in cultured VSMCs associates with inhibition of
β-catenin signaling, we tested whether quercetin similarly
affects this signaling conduit in MGP null arterial tissue.
Accumulation and nuclear localization of β-catenin protein,
indicative of activation of this pathway [47], were examined in
wild-type and Mgp-/- aortic tissue. In wild-type aortic tissue with
normally inactive β-catenin signaling [48], β-catenin protein
was not observed (Figure 6, Mgp+/+). In contrast, β-catenin
protein was readily detected by immunofluorescence in the
aortae of 5 week old Mgp-/- mice in which foci of alcian blue-
positive cartilaginous metaplasia develop in the tunica media
(Figure 6, Mgp-/-, - Querc). Further, in the quercetin-treated
Mgp-/- mice we did not detect any accumulation of β-catenin
protein in the vessel media (Figure 6, Mgp-/- + Querc),
suggesting that the in vivo morphological effects of quercetin
correlated with attenuation of β-catenin signaling. To further
clarify the relationship between β-catenin activation and
calcifying chondrogenic metaplasia in vivo, we determined the
location of cells with active β-catenin within arterial tissue.
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Figure 2.  Inhibition of β-catenin signaling attenuates chondrogenic transformation of cultured VSMCs.  Rat A10 VSMCs
stably-expressing a β-catenin-responsive luciferase transgene were induced to undergo chondrogenesis in high-density micromass
culture in chondrogenic medium (ChoM) containing TGF-β3. A, VSMCs form cartilaginous GAG-positive nodules as detected by
Alcian blue stain, in ChoM (- Querc). In the presence of 50 µmol/L Quercetin (ChoM + Querc) both the number and size of the
nodules is reduced. B-E, Expression of β-catenin-dependent luciferase reporter (B,D) and deposition of GAG-rich matrix, quantified
by extraction of Alcian blue stain normalized to cell number (C,E), in VSMCs cultured in ChoM in the presence or absence of
quercetin (B,C) or the β-catenin signaling pathway inhibitor Dkk1 (D,E). N=4.
doi: 10.1371/journal.pone.0076210.g002
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Figure 3.  Quercetin attenuates chondrogenic transformation and β-catenin activation in primary VSMCs.  A, Quercetin
reduces deposition of GAG-positive matrix in VSMCs induced to undergo chondrogensis in high-density micromass culture in
chondrogenic medium (ChoM). Quantitation of GAG deposition (left graph) and cell death, detected by LDH release into the culture
medium (right graph), in the presence or absence of 50 µmol/L quercetin. N=4. B-C, Real-time PCR analysis of markers of
chondrogenesis (B) and β-catenin target genes (C) in VSMC micromass cultures treated with ChoM and quercetin as indicated.
N=4. D, Quantitation of GAG deposition by VSMC micromass cultures treated with ChoM in the presence or absence of 0.5 µg/mL
Dkk1. N=4.
doi: 10.1371/journal.pone.0076210.g003
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Nuclear β-catenin protein was detected in chondrocyte-like
cells, which appear as rounded cells surrounded by alcian blue
positive GAG-rich matrix, in the Mgp-/- aortae (Figure 6,
insets), indicating that activation of the β-catenin signaling
associates with chondrogenic transformation in VSM in vivo.
Discussion
Data from this study demonstrate that MGP null vascular
disease associates primarily with chondrogenic but not
osteogenic transformation of VSM as we did not detect
expression of the key regulator of osteogenesis osterix or
induction of Msx2 in calcified Mgp-/- aortae. Similarly, a
Figure 4.  Quercetin reduces calcium accrual in Mgp-/- mice.  A-B, Total calcium in aortic tissue from 5 week old untreated
Mgp-/- mice (N=8) or Mgp-/- mice treated with 0.02% w/w dietary quercetin for 2 weeks after weaning (A; N=16) or for 5 weeks from
birth through weaning (B; N=9). Heterzygous (Mgp+/-) mice served as control (N=6). C, Von Kossa stain for calcified matrix
deposition in aortic tissue from Mgp+/-, untreated Mgp-/-, and quercetin-treated Mgp-/- animals. Sections from 2 representative
animals are shown. Arrows denote chondrogenic metaplasia. Scale = 50 µm.
doi: 10.1371/journal.pone.0076210.g004
Quercetin impedes VSMC chondrogenic transformation
PLOS ONE | www.plosone.org 10 September 2013 | Volume 8 | Issue 9 | e76210
previous study suggested chondrogenic transformation as a
major cell fate of the Mgp-/- VSM [13]. Of note, stimulation of
the β-catenin signaling pathway can promote chondrogenic
differentiation of mesenchymal cells in a Sox-9-dependent
manner [49] and in our system we also detected an increase in
both β-catenin activity and Sox-9 expression. Although
activation of canonical β-catenin signaling is broadly linked to
cardiovascular disorders [35,48,50], our study is the first to our
knowledge to demonstrate activation of this signaling pathway
in VSM undergoing chondrogenic transformation in vitro and in
vivo.
The origin of increased β-catenin activity in the Mgp-/- aortae
deserves further inquiry. The canonical Wnt ligands expressed
in the Mgp-/- aortae are present at very low levels, in contrast
to the robust induction of Wnt3a and Wnt7a reported in the
diabetic model. The observed dramatic reduction in expression
of the β-catenin pathway antagonist sclerostin may contribute
to activation of the pathway in the Mgp-/- model, and non-
canonical agonists of this signaling may also play a role. For
example, enzyme transglutaminase 2 (TG2), an important
regulator of β-catenin in calcifying VSM [24,51], accumulates in
Mgp-/- vessels in vivo [42] and is induced in VSMCs
undergoing chondrogenic differentiation in vitro (Figure 3B).
Taking into account that quercetin inhibits TG2 via direct
binding [12] it is possible that modulation of TG2 enzymatic
Table 4. Changes in osteogenic gene expression in aortas
from Mgp-/- mice treated with quercetin compared to




AlpI Alkaline phosphatase -2.09** 0.032
Anxa5 Annexin 5 -1.90** 0.010
Bmpr1b BMP receptor, type 1B -2.94** 0.006
Col14a1 Collagen type XIV, alpha 1 -4.28** 0.008
Col1a2 Collagen type I, alpha 2 -3.18** 0.043
Col4a2 Collagen type IV, alpha 2 -2.63** 0.035
Col6a1 Collagen type VI, alpha 1 -2.53** 0.048
Col6a2 Collagen type VI, alpha 2 -3.76** 0.015
Fgf3 Fibroblast growth factor 3 -6.78** 0.002
Fgfr1 Fibroblast growth factor receptor 1 -2.19** 0.014
Itga3 Integrin alpha 3 -2.03** 0.027
Itgav Integrin alpha V -3.17** 0.002
Mmp8 Matrix metalloproteinase 8 -4.20** 0.051
Smad1 MAD homolog 1 -1.48** 0.017
Tgfb3 Transforming growth factor, beta 3 -2.77** 0.001
Tgfbr1 Transforming growth factor receptor, beta 1 -3.19** 0.043
Col10a1 Collagen type X, alpha 1 -8.07** 0.105
Mmp10 Matrix metallopeptidase 10 -7.06** 0.145
Tissue from 4.5 week old animals was analyzed using a qRT-PCR-based
microarray N=5. *, p<0.05; ** p<0.01.
doi: 10.1371/journal.pone.0076210.t004
activity is central in chondrogenic metaplasia of VSM and its
prevention. Current studies are underway to address this
possibility.
Although quercetin drastically attenuated chondrogenic
metaplasia and its calcification, and intercepted chondrogenic
transformation of VSM as evidenced by attenuated expression
of pro-chondrogenic master regulators Sox9, Twist1, and
Runx2, the overall calcium accrual in Mgp-/- blood vessels was
only partially alleviated by this flavonoid. About one-half of total
mineral remained as deposits along the elastic lamellae,
supporting the model that elastocalcinosis may precede
chondrocyte-like transformation in VSM [52] and consistent
with the model in which MGP acts as a direct inhibitor of tissue
calcification by binding to small calcium phosphate precipitates
and/or the elastic lamellae, thereby preventing nucleation and
growth of mineral crystals (reviewed in [53]) This finding
challenges the perception of MGP-null arterial disease as
primarily a product of ectopic chondrogenesis resulting in
calcification [13], and emphasizes the importance of
elastocalcinosis in this pathology.
Attenuation of chondrogenic transformation in cultured
VSMCs by quercetin associated with inhibition of β-catenin
signaling, and in the Mgp-/- aortae quercetin treatment blocked
accumulation and nuclear localization of β-catenin protein,
supporting a role for this pathway in the phenotypic instability of
VSM. While inhibition of β-catenin signaling may be one of the
major mechanisms of quercetin action in this system, the
possible contribution of other known quercetin activities
including anti-inflammatory and anti-oxidative effects cannot be
excluded. However, the equally low cell proliferation in Mgp-/-
and wild type vessels demonstrated in this study and earlier
[13] indicate that cartilaginous metaplasia is not linked to
hyperproliferation and suggest a limited role for the anti-
proliferative activity of quercetin. While the exact mechanisms
whereby quercetin achieves a reduction in cartilaginous
metaplasia are not definitively proven, the data support a role
for inhibition of β-catenin signaling as a significant part of the
action.
In conclusion, this study adds to the growing understanding
of the complexity of MGP-mediated effects on vascular tissue
by adding the β-catenin signaling pathway to the MGP-
modulated cellular network that already includes BMP [54] and
Notch [55] conduits, and by showing that MGP may regulate
elastocalcinosis even when chondrogenic transformation is
suppressed. In addition, the presented studies contribute to the
mechanistic understanding of the beneficial effects of quercetin
in cardiovascular disease and identify a potential therapeutic
approach to the calcifying cartilaginous metaplasia of VSM with
quercetin that stands out as a pharmacological tool with
remarkably wide safety margin. Of note, the effects of quercetin
delivered in drinking water or via breast milk are similar in
Mgp-/- mice indicating that dietary supplement of quercetin in
breastfeeding females should be considered carefully for
possible effects on infants.
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Figure 5.  Quercetin prevents chondroplasia and improves vessel morphology in Mgp-/- mice.  A, Serial sections spaced 100
µm apart through a 1 mm segment of descending aorta from each animal were analyzed. B, Representative images of serial
sections from Mgp+/- (N=3), untreated Mgp-/- (N=5), and quercetin-treated Mgp-/- (N=6) animals stained with Alcian blue. Dashed
lines denote the proportional presence of chondroplastic lesions in the vessel wall. Scale = 50 µm. C-D, Quantitative analysis of the
serial sections of aortae show that quercetin diet reduces the percentage of vessel circumference occupied by chondrogenic lesions
(C) and the cross-sectional thickness of the medial aorta (D).
doi: 10.1371/journal.pone.0076210.g005
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Table 5. Changes in expression of genes related to
chondrogenic differentiation in Mgp-/- versus wild-type and
in quercetin-treated Mgp-/- (Mgp-/- +Q) versus untreated
Mgp-/- aortic tissue from 4.5 week old animals analyzed by
qRT-PCR-based microarray.







Col11a1 Collagen, type XI 4.34*** 0.005 -3.79*** 0.006
Col12a1 Collagen, type XII 9.86*** 0.029 -3.94*** 0.031
Col1a1 Collagen, type I 7.28*** 0.034 -2.58*** 0.143




75.92*** 0.031 -3.26*** 0.058
Dmp1 Dentin matrix protein 1 12.19*** 0.048 -4.52*** 0.070








3.48*** 0.010 -2.01*** 0.028
Transcription factors












1.69*** 0.040 -2.19*** 0.027
Vdr Vitamin D receptor 5.38*** 0.008 -1.03*** 0.740
N=5. *, p<0.05; ** p<0.01; *** p<0.001.
doi: 10.1371/journal.pone.0076210.t005
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Figure 6.  Quercetin blocks accumulation and nuclear localization of β-catenin protein in Mgp-/- aortae.  Immunostaining for
β-catenin (white, red) [nuclei counterstained with DAPI (blue)] and Alcian blue staining for GAG deposition on adjacent sections of
aortae from Mgp+/+, untreated Mgp-/-, and quercetin-treated Mgp-/- animals shows that β-catenin protein is detected only in
untreated Mgp-/- arterial tissue. Scale = 30 µm. Inset panels show higher magnification of representative nuclei, demonstrating co-
localization of β-catenin with DAPI in the Mgp-/- aorta in rounded chondrocyte-like cells surrounded by cartilaginous GAG-rich
matrix.
doi: 10.1371/journal.pone.0076210.g006
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